SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nasdaq to delist BioXcel Therapeutics after Chapter 11 filing

Nasdaq notified BioXcel Therapeutics that its common stock will be delisted due to its Chapter 11 filing on Aug. 27, 2026. Trading will be suspended at the open on Sept. 8, 2026, with a Form 25-NSE to follow.

BTAI

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories